Zacks Investment Research upgraded Protalix Biotherapeutics Inc (NYSE:PLX) to Hold in a report released today.
- Updated: September 25, 2016
Zacks Investment Research has upgraded Protalix Biotherapeutics Inc (NYSE:PLX) to Hold in a report released on 9/21/2016.
Just yesterday Protalix Biotherapeutics Inc (NYSE:PLX) traded -4.25% lower at $0.60. Protalix Biotherapeutics Inc’s 50-day moving average is $0.62 and its 200-day moving average is $0.74. The last stock price is down -22.68% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 72,266 shares of the stock were exchanged, down from an average trading volume of 117,908
See Chart Below
Protalix Biotherapeutics Inc has a price-earnings ratio of 1.13 with a one year low of $0.56 and a one year high of $1.40 PLX’s total market value is presently $0.
A total of 1 equity analyst has released a ratings update on PLX. One equity analyst rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $1.75.
Brief Synopsis About Protalix Biotherapeutics Inc (NYSE:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that is approved for marketing in the United States, Brazil, Israel and other markets. The Company developed Elelyso using ProCellEx system and is focused on utilizing the system to develop a pipeline of clinically superior versions of recombinant therapeutic proteins that primarily target pharmaceutical markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company's product pipeline includes PRX-102, PRX-106, PRX-112 and PRX-110.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.